Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Transient opening of trimeric prefusion RSV F proteins.

Gilman MSA, Furmanova-Hollenstein P, Pascual G, B van 't Wout A, Langedijk JPM, McLellan JS.

Nat Commun. 2019 May 8;10(1):2105. doi: 10.1038/s41467-019-09807-5.

2.

HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry.

Eggink D, Bontjer I, de Taeye SW, Langedijk JPM, Berkhout B, Sanders RW.

J Biol Chem. 2019 Apr 12;294(15):5736-5746. doi: 10.1074/jbc.RA119.007360. Epub 2019 Jan 29.

3.

Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor.

Kalbermatter D, Shrestha N, Ader-Ebert N, Herren M, Moll P, Plemper RK, Altmann KH, Langedijk JP, Gall F, Lindenmann U, Riedl R, Fotiadis D, Plattet P.

Virus Res. 2019 Jan 2;259:28-37. doi: 10.1016/j.virusres.2018.10.003. Epub 2018 Oct 5.

PMID:
30296457
4.

A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers.

Rutten L, Lai YT, Blokland S, Truan D, Bisschop IJM, Strokappe NM, Koornneef A, van Manen D, Chuang GY, Farney SK, Schuitemaker H, Kwong PD, Langedijk JPM.

Cell Rep. 2018 Apr 10;23(2):584-595. doi: 10.1016/j.celrep.2018.03.061.

5.

Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.

Jones HG, Ritschel T, Pascual G, Brakenhoff JPJ, Keogh E, Furmanova-Hollenstein P, Lanckacker E, Wadia JS, Gilman MSA, Williamson RA, Roymans D, van 't Wout AB, Langedijk JP, McLellan JS.

PLoS Pathog. 2018 Mar 6;14(3):e1006935. doi: 10.1371/journal.ppat.1006935. eCollection 2018 Mar.

6.

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.

Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P, Berg JVD, Kwanten L, Ginderen MV, Verheyen N, Vranckx L, Jaensch S, Arnoult E, Voorzaat R, Gallup JM, Larios-Mora A, Crabbe M, Huntjens D, Raboisson P, Langedijk JP, Ackermann MR, McLellan JS, Vendeville S, Koul A.

Nat Commun. 2017 Aug 1;8(1):167. doi: 10.1038/s41467-017-00170-x.

7.

Peptide mimetics of immunoglobulin A (IgA) and FcαRI block IgA-induced human neutrophil activation and migration.

Heineke MH, van der Steen LPE, Korthouwer RM, Hage JJ, Langedijk JPM, Benschop JJ, Bakema JE, Slootstra JW, van Egmond M.

Eur J Immunol. 2017 Oct;47(10):1835-1845. doi: 10.1002/eji.201646782. Epub 2017 Sep 6.

8.

Dimerization Efficiency of Canine Distemper Virus Matrix Protein Regulates Membrane-Budding Activity.

Bringolf F, Herren M, Wyss M, Vidondo B, Langedijk JP, Zurbriggen A, Plattet P.

J Virol. 2017 Jul 27;91(16). pii: e00521-17. doi: 10.1128/JVI.00521-17. Print 2017 Aug 15.

9.

HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.

Eggink D, de Taeye SW, Bontjer I, Klasse PJ, Langedijk JPM, Berkhout B, Sanders RW.

J Virol. 2016 Nov 14;90(23):10587-10599. doi: 10.1128/JVI.01616-16. Print 2016 Dec 1.

10.

Molecular mechanism of respiratory syncytial virus fusion inhibitors.

Battles MB, Langedijk JP, Furmanova-Hollenstein P, Chaiwatpongsakorn S, Costello HM, Kwanten L, Vranckx L, Vink P, Jaensch S, Jonckers TH, Koul A, Arnoult E, Peeples ME, Roymans D, McLellan JS.

Nat Chem Biol. 2016 Feb;12(2):87-93. doi: 10.1038/nchembio.1982. Epub 2015 Dec 7.

11.

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JPM.

Nat Commun. 2015 Sep 3;6:8143. doi: 10.1038/ncomms9143.

12.

Sequential conformational changes in the morbillivirus attachment protein initiate the membrane fusion process.

Ader-Ebert N, Khosravi M, Herren M, Avila M, Alves L, Bringolf F, Örvell C, Langedijk JP, Zurbriggen A, Plemper RK, Plattet P.

PLoS Pathog. 2015 May 6;11(5):e1004880. doi: 10.1371/journal.ppat.1004880. eCollection 2015 May.

13.

Identification of amino acid substitutions with compensational effects in the attachment protein of canine distemper virus.

Sattler U, Khosravi M, Avila M, Pilo P, Langedijk JP, Ader-Ebert N, Alves LA, Plattet P, Origgi FC.

J Virol. 2014 Jul;88(14):8057-64. doi: 10.1128/JVI.00454-14. Epub 2014 May 7.

14.

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.

Lutje Hulsik D, Liu YY, Strokappe NM, Battella S, El Khattabi M, McCoy LE, Sabin C, Hinz A, Hock M, Macheboeuf P, Bonvin AM, Langedijk JP, Davis D, Forsman Quigley A, Aasa-Chapman MM, Seaman MS, Ramos A, Poignard P, Favier A, Simorre JP, Weiss RA, Verrips CT, Weissenhorn W, Rutten L.

PLoS Pathog. 2013 Mar;9(3):e1003202. doi: 10.1371/journal.ppat.1003202. Epub 2013 Mar 7.

15.

A sweet surprise for HIV broadly neutralizing antibodies.

Langedijk JP, Schuitemaker H.

Nat Med. 2012 Nov;18(11):1616-7. doi: 10.1038/nm.2993.

PMID:
23135511
16.

Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.

Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, Langedijk JP, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Virol. 2012 Nov;86(22):12115-28. doi: 10.1128/JVI.01632-12. Epub 2012 Aug 29.

17.

Peptides based on the presenilin-APP binding domain inhibit APP processing and Aβ production through interfering with the APP transmembrane domain.

Esselens C, Sannerud R, Gallardo R, Baert V, Kaden D, Serneels L, De Strooper B, Rousseau F, Multhaup G, Schymkowitz J, Langedijk JP, Annaert W.

FASEB J. 2012 Sep;26(9):3765-78. doi: 10.1096/fj.11-201368. Epub 2012 Jun 1.

PMID:
22661005
18.

Structure-based design for high-hanging vaccine fruits.

Back JW, Langedijk JP.

Adv Immunol. 2012;114:33-50. doi: 10.1016/B978-0-12-396548-6.00002-0. Review.

PMID:
22449777
19.

Structural rearrangements of the central region of the morbillivirus attachment protein stalk domain trigger F protein refolding for membrane fusion.

Ader N, Brindley MA, Avila M, Origgi FC, Langedijk JP, Örvell C, Vandevelde M, Zurbriggen A, Plemper RK, Plattet P.

J Biol Chem. 2012 May 11;287(20):16324-34. doi: 10.1074/jbc.M112.342493. Epub 2012 Mar 19.

20.

Canine distemper virus infects canine keratinocytes and immune cells by using overlapping and distinct regions located on one side of the attachment protein.

Langedijk JP, Janda J, Origgi FC, Örvell C, Vandevelde M, Zurbriggen A, Plattet P.

J Virol. 2011 Nov;85(21):11242-54. doi: 10.1128/JVI.05340-11. Epub 2011 Aug 17.

21.

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW.

J Virol. 2011 Oct;85(20):10785-97. doi: 10.1128/JVI.05331-11. Epub 2011 Aug 10.

22.

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A.

Science. 2011 Aug 12;333(6044):850-6. doi: 10.1126/science.1205669. Epub 2011 Jul 28.

23.

Helical peptide arrays for lead identification and interaction site mapping.

Langedijk JP, Zekveld MJ, Ruiter M, Corti D, Back JW.

Anal Biochem. 2011 Oct 1;417(1):149-55. doi: 10.1016/j.ab.2011.06.002. Epub 2011 Jun 12.

PMID:
21708118
24.

Identification of key residues in virulent canine distemper virus hemagglutinin that control CD150/SLAM-binding activity.

Zipperle L, Langedijk JP, Orvell C, Vandevelde M, Zurbriggen A, Plattet P.

J Virol. 2010 Sep;84(18):9618-24. doi: 10.1128/JVI.01077-10. Epub 2010 Jul 14.

25.

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A.

PLoS One. 2010 Jan 20;5(1):e8805. doi: 10.1371/journal.pone.0008805.

26.

Conserved leucine residue in the head region of morbillivirus fusion protein regulates the large conformational change during fusion activity.

Plattet P, Langedijk JP, Zipperle L, Vandevelde M, Orvell C, Zurbriggen A.

Biochemistry. 2009 Sep 29;48(38):9112-21. doi: 10.1021/bi9008566.

PMID:
19705836
27.

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.

Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, Berkhout B, Sanders RW.

J Biol Chem. 2009 Sep 25;284(39):26941-50. doi: 10.1074/jbc.M109.004416. Epub 2009 Jul 17.

28.

Spine-shaped gold protrusions improve the adherence and electrical coupling of neurons with the surface of micro-electronic devices.

Hai A, Dormann A, Shappir J, Yitzchaik S, Bartic C, Borghs G, Langedijk JP, Spira ME.

J R Soc Interface. 2009 Dec 6;6(41):1153-65. doi: 10.1098/rsif.2009.0087. Epub 2009 May 27.

29.

Heterologous stacking of prion protein peptides reveals structural details of fibrils and facilitates complete inhibition of fibril growth.

Boshuizen RS, Schulz V, Morbin M, Mazzoleni G, Meloen RH, Langedijk JP.

J Biol Chem. 2009 May 8;284(19):12809-20. doi: 10.1074/jbc.M809151200. Epub 2009 Mar 19.

30.

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.

Bogers WM, Davis D, Baak I, Kan E, Hofman S, Sun Y, Mortier D, Lian Y, Oostermeijer H, Fagrouch Z, Dubbes R, van der Maas M, Mooij P, Koopman G, Verschoor E, Langedijk JP, Zhao J, Brocca-Cofano E, Robert-Guroff M, Srivastava I, Barnett S, Heeney JL.

Virology. 2008 Dec 20;382(2):217-25. doi: 10.1016/j.virol.2008.09.016. Epub 2008 Oct 22.

31.

Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.

J Virol. 2008 Jul;82(13):6678-88. doi: 10.1128/JVI.00352-08. Epub 2008 Apr 23.

32.

SUMO assay with peptide arrays on solid support: insights into SUMO target sites.

Schwamborn K, Knipscheer P, van Dijk E, van Dijk WJ, Sixma TK, Meloen RH, Langedijk JP.

J Biochem. 2008 Jul;144(1):39-49. doi: 10.1093/jb/mvn039. Epub 2008 Mar 15.

PMID:
18344540
33.
35.

Two-rung model of a left-handed beta-helix for prions explains species barrier and strain variation in transmissible spongiform encephalopathies.

Langedijk JP, Fuentes G, Boshuizen R, Bonvin AM.

J Mol Biol. 2006 Jul 21;360(4):907-20. Epub 2006 Jun 5.

PMID:
16782127
36.

Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q.

Veerhuis R, Boshuizen RS, Morbin M, Mazzoleni G, Hoozemans JJ, Langedijk JP, Tagliavini F, Langeveld JP, Eikelenboom P.

Neurobiol Dis. 2005 Jun-Jul;19(1-2):273-82.

PMID:
15837583
37.

An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds.

Boshuizen RS, Langeveld JP, Salmona M, Williams A, Meloen RH, Langedijk JP.

Anal Biochem. 2004 Oct 15;333(2):372-80.

PMID:
15450815
38.

Measles virus (MV) hemagglutinin: evidence that attachment sites for MV receptors SLAM and CD46 overlap on the globular head.

Massé N, Ainouze M, Néel B, Wild TF, Buckland R, Langedijk JP.

J Virol. 2004 Sep;78(17):9051-63.

39.

New transport peptides broaden the horizon of applications for peptidic pharmaceuticals.

Langedijk JP, Olijhoek T, Schut D, Autar R, Meloen RH.

Mol Divers. 2004;8(2):101-11.

PMID:
15209161
40.

Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein.

de Waal L, Yüksel S, Brandenburg AH, Langedijk JP, Sintnicolaas K, Verjans GM, Osterhaus AD, de Swart RL.

J Virol. 2004 Feb;78(4):1775-81.

41.

Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis.

Antonis AF, Schrijver RS, Daus F, Steverink PJ, Stockhofe N, Hensen EJ, Langedijk JP, van der Most RG.

J Virol. 2003 Nov;77(22):12067-73.

42.

Design of synthetic peptides for diagnostics.

Meloen RH, Puijk WC, Langeveld JP, Langedijk JP, Timmerman P.

Curr Protein Pept Sci. 2003 Aug;4(4):253-60. Review.

PMID:
14529532
43.

A structural model of pestivirus E(rns) based on disulfide bond connectivity and homology modeling reveals an extremely rare vicinal disulfide.

Langedijk JP, van Veelen PA, Schaaper WM, de Ru AH, Meloen RH, Hulst MM.

J Virol. 2002 Oct;76(20):10383-92.

44.

Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera.

Khor IW, Lin T, Langedijk JP, Johnson JE, Manchester M.

J Virol. 2002 May;76(9):4412-9.

45.

Translocation activity of C-terminal domain of pestivirus Erns and ribotoxin L3 loop.

Langedijk JP.

J Biol Chem. 2002 Feb 15;277(7):5308-14. Epub 2001 Oct 22.

48.

A bovine respiratory syncytial virus strain with mutations in subgroup-specific antigenic domains of the G protein induces partial heterologous protection in cattle.

Schrijver RS, Langedijk JP, Middel WG, Kramps JA, Rijsewijk FA, van Oirschot JT.

Vet Microbiol. 1998 Oct;63(2-4):159-75.

PMID:
9850996
50.

Comparison of DNA application methods to reduce BRSV shedding in cattle.

Schrijver RS, Langedijk JP, Keil GM, Middel WG, Maris-Veldhuis M, Van Oirschot JT, Rijsewijk FA.

Vaccine. 1998 Jan-Feb;16(2-3):130-4.

PMID:
9607020

Supplemental Content

Loading ...
Support Center